Replies

This is an Indian report, quoting an announcement at the SPIEF in June of this year.

Clearly the stats are required, and this is phrased as an early trial, which would suggest Phase I equivalent. But they aren’t going to be doing any Phase I trials unless they saw something encouraging in other work.

Phase I is a test for safety, mostly. Phase II is to see if there is in fact performance against the designated goal. Phase III is the test to see if that performance exceeds the current gold standard of treatment. If it does, then it becomes the new gold standard.

An AI query of SPIEF and cancer found the details. The initial study was of 47 people.

Quoting what the AI found: Phase-1 clinical trials began in June 2025 and have concluded, with results indicating significant tumor reduction, slowed growth, and in some cases, complete elimination of tumors.

It is not unusual for a Phase I trial for cancer to have volunteers who actually have a diagnosis. For other diseases Phase I might have volunteers with no disease, because the focus is just proving safety, not performance. Though this process apparently DID show performance.

Note the technique is very personalized. There is no mass produced vaccine for the population. It is tailored to the individual.

Ask an AI for SPIEF and cancer. Lots of detail.